Metformin improves healthspan and lifespan in mice

Nature Communications

Volumn 4, Issue , 2013, Pages

  Martin Montalvo, Alejandro ^a   Mercken, Evi M ^a   Mitchell, Sarah J ^a,b,c   Palacios, Hector H ^a   Mote, Patricia L ^d   Scheibye Knudsen, Morten ^a   Gomes, Ana P ^e   Ward, Theresa M ^a   Minor, Robin K ^f   Blouin, Marie José ^g   Schwab, Matthias ^f   Pollak, Michael ^a   Zhang, Yongqing ^a   Yu, Yinbing ^h   Becker, Kevin G ^a   Bohr, Vilhelm A ^a   Ingram, Donald K ⁱ   Sinclair, David A ^e   Wolf, Norman S ^j   Spindler, Stephen R ^d   Bernier, Michel ^a   De Cabo, Rafael ^a   more..

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h Laboratory of Membrane Biochemistry and Biophysics   (United States)

ⁱ PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN;

AGING; ANTIOXIDANT; DIABETES; DRUG; EPIDEMIOLOGY; HORMONE; OXIDATION; PROTEIN; PUBLIC HEALTH; RODENT;

ANIMAL EXPERIMENT; ARTICLE; CALORIC INTAKE; CALORIC RESTRICTION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; INSULIN SENSITIVITY; LIFESPAN; LONGEVITY; MALE; MOUSE; NONHUMAN; PHYSICAL PERFORMANCE;

MUS;

EID: 84881347302     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3192     Document Type: Article

References (51)

1. He, L. et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137, 635-646 (2009).
2. Correia, S. et al. Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini. Rev. Med. Chem. 8, 1343-1354 (2008).
3. Pollak, M. N. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 9, 778-790 (2012).
4. Libby, G. et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32, 1620-1625 (2009).
5. Giovannucci, E. et al. Diabetes and cancer: a consensus report. Diabetes Care 33, 1674-1685 (2010).
6. Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392-395 (2009).
7. Baur, J. A. et al. Resveratrol improves health and survival of mice on a highcalorie diet. Nature 444, 337-342 (2006). (Pubitemid 44764104)
8. Martin-Montalvo, A., Villalba, J. M., Navas, P. & de Cabo, R. NRF2, cancer and calorie restriction. Oncogene 30, 505-520 (2011).
9. Anisimov, V. N. et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging 3, 148-157 (2011).
10. Onken, B. & Driscoll, M. Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans healthspan via AMPK, LKB1, and SKN-1. PLoS One 5, e8758 (2010).
11. Smith, Jr D. L. et al. Metformin supplementation and life span in Fischer-344 rats. J. Gerontol. A Biol. Sci. Med. Sci. 65, 468-474 (2010).
12. Anisimov, V. N. et al. Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging (Albany NY) 2, 945-958 (2010).
13. Slack, C., Foley, A. & Partridge, L. Activation of AMPK by the putative dietary restriction mimetic metformin is insufficient to extend lifespan in Drosophila. PLoS ONE 7, e47699 (2012).
14. Dhahbi, J. M., Mote, P. L., Fahy, G. M. & Spindler, S. R. Identification of potential caloric restriction mimetics by microarray profiling. Physiol. Genomics 23, 343-350 (2005). (Pubitemid 44437970)
15. Spindler, S. R. Use of microarray biomarkers to identify longevity therapeutics. Aging Cell 5, 39-50 (2006). (Pubitemid 43348961)
16. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174 (2001). (Pubitemid 32995375)
17. Larsson, O. et al. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc. Natl Acad. Sci. USA 109, 8977-8982 (2012).
18. Saeedi, R. et al. Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms. Am. J. Physiol. 294, H2497-H2506 (2008).
19. Ben Sahra, I. et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71, 4366-4372 (2011).
20. Hardie, D. G., Ross, F. A. & Hawley, S. A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13, 251-262 (2012).
21. Brunmair, B. et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53, 1052-1059 (2004). (Pubitemid 38436618)
22. El-Mir, M. Y. et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275, 223-238 (2000).
23. Martin-Montalvo, A. & de Cabo, R. Mitochondrial metabolic reprogramming induced by calorie restriction. Antioxid. Redox Signal 19, 310-320 (2012).
24. Testa, C. M., Sherer, T. B. & Greenamyre, J. T. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res. 134, 109-118 (2005). (Pubitemid 40403643)
25. Hariharakrishnan, J., Satpute, R. M., Prasad, G. B. & Bhattacharya, R. Oxidative stress mediated cytotoxicity of cyanide in LLC-MK2 cells and its attenuation by alpha-ketoglutarate and N-acetyl cysteine. Toxicol. Lett. 185, 132-141 (2009).
26. Algire, C. et al. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev. Res. (Phila) 5, 536-543 (2012).
27. Halicka, H. D. et al. Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling. Aging 3, 1028-1038 (2011).
28. Hou, X. et al. Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem. Biophys. Res. Commun. 396, 199-205 (2010).
29. Pierotti, M. A. et al. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene 32, 1475-1487 (2013).
30. Holst, H., Eldrup, E., Guldstad, N. H., Bülow, H. H. & Christensen, H. R. [Metformin associated with lactic acidosis in treatment of type 2 diabetes. Ugeskr. Laeger. 174, 1598-1602 (2012).
31. Alley, D. E. et al. Changes in weight at the end of life: characterizing weight loss by time to death in a cohort study of older men. Am. J. Epidemiol. 172, 558-565 (2010).
32. Pearson, K. J. et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell. Metab. 8, 157-168 (2008).
33. Sheldon, W. G., Bucci, T. J., Hart, R.W. & Turturro, A. Age-related neoplasia in a lifetime study of ad libitum-fed and food-restricted B6C3F1 mice. Toxicol. Pathol. 23, 458-476 (1995).
34. Pyra, K. A., Saha, D. C. & Reimer, R. A. Prebiotic fiber increases hepatic acetyl CoA carboxylase phosphorylation and suppresses glucose-dependent insulinotropic polypeptide secretion more effectively when used with metformin in obese rats. J. Nutr. 142, 213-220 (2012).
35. Collier, C. A., Bruce, C. R., Smith, A. C., Lopaschuk, G. & Dyck, D. J. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 291, E182-E189 (2006). (Pubitemid 44035324)
36. Nerstedt, A. et al. AMP-activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3). Diabetologia 53, 2406-2416 (2010).
37. Radziuk, J., Bailey, C. J., Wiernsperger, N. F. & Yudkin, J. S. Metformin and its liver targets in the treatment of type 2 diabetes. Curr. Drug Targets Immune Endocr. Metabol. Disord. 3, 151-169 (2003).
38. Kim, Y. D. et al. Metformin inhibits hepatic gluconeogenesis through AMPactivated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 57, 306-314 (2008).
39. Gonzalez-Barroso, M. M. et al. Fatty acids revert the inhibition of respiration caused by the antidiabetic drug metformin to facilitate their mitochondrial beta-oxidation. Biochim. Biophys. Acta 1817, 1768-1775 (2012).
40. Vives, M. et al. Metformin-associated lactic acidosis: incidence, diagnosis, prognostic factors and treatment. Rev. Esp. Anestesiol. Reanim. 59, 276-279 (2012).
41. Larsen, S. et al. Metformin-treated patients with type 2 diabetes have normal mitochondrial complex I respiration. Diabetologia 55, 443-449 (2012).
42. Kane, D. A. et al. Metformin selectively attenuates mitochondrial H2O2 emission without affecting respiratory capacity in skeletal muscle of obese rats. Free Radic. Biol. Med. 49, 1082-1087 (2010).
43. Sum, C. F. et al. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet. Med. 9, 61-65 (1992).
44. Szabo, G. & Csak, T. Inflammasomes in liver diseases. J. Hepatol. 57, 642-654 (2012).
45. Brasier, A. R. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc. Res. 86, 211-218 (2010).
46. De Luca, C. & Olefsky, J. M. Inflammation and insulin resistance. FEBS Lett. 582, 97-105 (2008). (Pubitemid 50010731)
47. Cheadle, C., Vawter, M. P., Freed, W. J. & Becker, K. G. Analysis of microarray data using Z score transformation. J. Mol. Diagn. 5, 73-81 (2003). (Pubitemid 36553428)
48. Lee, C. et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci. Transl. Med. 4, 124-127 (2012).
49. Kim, S. Y. & Volsky, D. J. PAGE: parametric analysis of gene set enrichment. BMC Bioinform. 6, 144 (2005).
50. Padilla, S. et al. Demethoxy-Q, an intermediate of coenzyme Q biosynthesis, fails to support respiration in Saccharomyces cerevisiae and lacks antioxidant activity. J. Biol. Chem. 279, 25995-26004 (2004). (Pubitemid 38798741)
51. Bernier, M. et al. Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein. J. Biol. Chem. 286, 19270-19279 (2011).